Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomized, Parallel-group, Rater-blinded Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis Plus a Long Term Extension Period
Brief Summary: Primary objective was to assess the effectiveness evaluated by the time to failure of two doses of teriflunomide in comparison to interferon beta-1a in participants with relapsing Multiple Sclerosis \[MS\].

Secondary objectives were:

* To assess the effect of the two doses in comparison to interferon beta-1a on:

  * Frequency of relapses,
  * Fatigue,
  * Participant's satisfaction with treatment.
* To evaluate the safety and tolerability of the two doses in comparison to interferon beta-1a.

The study consisted of a core treatment period with a common end date defined as 48 weeks after randomization of the last participant, followed by an optional long-term extension treatment period until teriflunomide is commercially available in accordance with local regulations.


Options:
A: Arm Label: Teriflunomide 7 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: IFN-β-1a / 14 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon β-1a, Drug: Teriflunomide | Intervention Type: DRUG; Name: Interferon β-1a; Assigned to Arm(s): IFN-β-1a / 14 mg | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): IFN-β-1a / 14 mg, Teriflunomide 14 mg / 14 mg, Teriflunomide 7 mg / 14 mg
B: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Ocrelizumab 600 mg; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab | Arm Label: Ocrelizumab 1000 mg; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab | Arm Label: Avonex; Type: ACTIVE_COMPARATOR; Interventions: Drug: Avonex | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab 1000 mg, Ocrelizumab 600 mg | Intervention Type: DRUG; Name: Avonex; Assigned to Arm(s): Avonex
D: Arm Label: Interferon beta 1-a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta 1-a, Other: placebo | Arm Label: glatiramer acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: glatiramer acetate, Other: placebo | Arm Label: IFN and GA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta 1-a, Drug: glatiramer acetate | Intervention Type: DRUG; Name: Interferon beta 1-a; Assigned to Arm(s): IFN and GA, Interferon beta 1-a | Intervention Type: DRUG; Name: glatiramer acetate; Assigned to Arm(s): IFN and GA, glatiramer acetate | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Interferon beta 1-a, glatiramer acetate

Answer: A